Last Updated : May 29, 2025
Details
Generic Name:
vamorolone
Project Status:
Pending
Therapeutic Area:
Duchenne muscular dystrophy (DMD)
Manufacturer:
Kye Pharmaceuticals Inc.
Call for patient/clinician input open:
Brand Name:
Agamree
Project Line:
Reimbursement Review
Project Number:
SR0892-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : May 29, 2025